Compare PulteGroup, Inc. (PHM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? PulteGroup, Inc. trades at $110.09 (market cap $21.25B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: PulteGroup, Inc. is far larger — about 2.8× Spyre Therapeutics Inc. Common Stock's market cap, and PulteGroup, Inc. pays a 0.93% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PHM | SYRE | |
|---|---|---|
Market Cap | $21.25B | $7.52B |
Volume | 1,784,813 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $108.92 |
52-Week Low | $109.35 | $22.18 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $21.67B | $6.52B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $109.35, down 1.61% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with recent earnings misses in Q4 2025 and Q1 2026, though it beat expectations in Q2 2026. Fundamentally, the company maintains solid profitability with 11.62% net margin and attractive valuation at 11.4 P/E. Analyst consensus remains mixed with 45% buy ratings but a $139.64 price target suggesting 28% upside potential from current levels.
PHM presents a value opportunity with strong cash flow generation and dividend yield, though near-term headwinds from rising interest rates and housing affordability concerns create volatility. The stock's current discount to analyst targets and reasonable valuation metrics support long-term potential, but investors should monitor Q3 2026 earnings on October 22 for confirmation of business resilience.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
